DPY19L3 and breast carcinoma: Moreover, knockdown (KD) of DPY19L3 decreased VM capability in MDA-MB-231 human breast cancer cells, suggesting that DPY19L3-mediated C-mannosylated proteins regulate these phenomena and that DPY19L3 is a new molecular target for cancer therapy.